Sara Taveras Alam, MD
Hematology & Oncology · Houston, TXNPI 1184989527
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,751 of the $9,988 with a category attached, or 67.6%. It is spread thinly across 27 manufacturers, the largest accounting for just 22.1%. 2025 is the largest year on record at $5,837, 4.1 times the $1,410 reported in 2019.
Across 121 payments — averaging $82.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$2K
- Pfizer$2K
- Johnson & Johnson$2K
- AstraZeneca$1K
- Bristol Myers Squibb$570
- Adaptive Biotechnologies Corporation$321
- plus $2K from 21 others
What the payments were for
- Consulting fees$6,75168%
- Food & beverage$3,15332%
- Education$841%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 8 | $2,209 |
| Pfizer | 5 | $2,172 |
| Johnson & Johnson | 7 | $1,890 |
| AstraZeneca(2 entities) | 10 | $1,251 |
| Bristol Myers Squibb | 28 | $570 |
| Adaptive Biotechnologies Corporation | 8 | $321 |
| Jazz Pharmaceuticals Inc. | 3 | $289 |
| Janssen Research & Development, LLC | 1 | $146 |
| Amgen | 5 | $134 |
| Lilly USA, LLC | 8 | $133 |
| Astrazeneca UK Limited | 1 | $122 |
| Gilead | 1 | $122 |
| Bayer | 10 | $121 |
| Genmab U.S., Inc. | 3 | $65 |
| Novartis | 3 | $63 |
| Rigel Pharmaceuticals, Inc. | 3 | $51 |
| Incyte Corporation | 3 | $50 |
| Sanofi | 2 | $49 |
| Taiho Oncology, Inc. | 2 | $48 |
| Agios Pharmaceuticals, Inc. | 3 | $45 |
| Syndax Pharmaceuticals, Inc. | 1 | $26 |
| Stemline Therapeutics Inc. | 1 | $24 |
| Astellas Pharma US Inc | 1 | $22 |
| Beigene USA, Inc. | 1 | $22 |
| Eisai Inc. | 1 | $19 |
| Seagen Inc. | 1 | $14 |
| AMAG Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,988 in reported general payments places this provider in the 70th percentile of 838 hematology & oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IclusigPonatinib Hcl | 11 | $239,714 |
| VenclextaVenetoclax | 39 | $46,742 |
| Imatinib Mesylate | 16 | $13,954 |
| Ondansetron Hcl | 20 | $2,236 |
| ValacyclovirValacyclovir Hcl | 18 | $923 |
| Levofloxacin | 17 | $135 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Houston
- Devesh PandyaHouston$1.8M
- Elias JabbourHouston$1.3M
- Naval DaverHouston$853K
- Jorge Cortes-FrancoHouston$627K
- Courtney DinardoHouston$478K
- Prithviraj BoseHouston$463K
- Milind JavleHouston$326K
- Loretta NastoupilHouston$309K
- Boyu HuHouston$281K
- Luis CamachoHouston$276K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.